Features and outcome of selected trials with reported outcomes
| Trial . | Phase . | N . | Patients . | Risk group . | CR rate (%) . | 1-year PFS (%) . |
|---|---|---|---|---|---|---|
| ZUMA-5, axi-cel51 | 2 | 124 | R/R | Median previous line 3 POD24, 56% | 79 | 74 |
| ELARA, tisa-cel52 | 2 | 97 | R/R | Median previous line 4 POD24, 63% | 68 | 67 |
| TRANSCEND FL, liso-cel53 | 2 | 101 (3L+ cohort) | R/R | Median previous line 3 POD24, 54% | 94 | 81 |
| Mosunetuzumab19 | 2 | 90 | R/R | Median previous line 3 POD24, 52% | 60 | 58 |
| Epcoritamab20 | 1/2 | 128 | R/R | Median previous line 3 POD24, 42% | 63 | 18-month PFS, 49 |
| Odronextamab21 | 2 | 128 | R/R | Median previous line 3 POD24, 49% | 73 | 66 |
| InMIND, tafa-R2 vs R254 | 3 | 548 | R/R | Median previous line 1 POD24, 32% | 52 (tafa-R2) 41 (R2) | Median, 22.4 months (tafa-R2) 13.9 months (R2) |
| Mosunetuzumab-lenalidomide55 | 1b | 27 | R/R | Median previous line 1 POD24, 11% | 77 | Not reported |
| Epcoritamab-R256 | 1/2 | 111 | R/R | Median previous line 1 POD24, 38% | 87 | 21-month PFS, 80 |
| AZD048657 | 1 | 56 | R/R | Median previous line 3 POD24, 34% | 85 | 79 |
| Tazemetostat58 | 2 | 99 | R/R | Median previous line 2-3 POD24, 42%-59% (based on EZH2 mutation status) | 13 (EZH2 mutated), 4 (EZH2 wild type) | Median, 11-14 months |
| ROSEWOOD, ZO49 | 2 | 145 | R/R | Median previous line 3 POD24, 34% | 39 | Median, 28 months |
| Golcadomide with/without rituximab59 | 1/2 | 63 | R/R | Median previous line 4 (golcadomide monotherapy) Median previous line 3 (golcadomide-rituximab) | 42 (golcadomide monotherapy) 67 (golcadomide 0.4 mg + rituximab) | Median, 22 months (golcadomide monotherapy) |
| Iberdomide with obinutuzumab60 | 1/2 | 13 (FL + MZL cohort) | R/R | Median previous line 4 (all B-NHL) | 39 (FL + MZL) | Not reported |
| MORNINGSUN, mosunetuzumab22 | 1 | 30 | Front line, low tumor burden | FLIPI 3-5, 10% | 83 | Not reported |
| Mosunetuzumab-lenalidomide30 | 1b/2 | 37 | Front line, high tumor burden | Stage III-IV, 87% FLIPI 3-5, 46% | 82 | Not reported |
| Trial . | Phase . | N . | Patients . | Risk group . | CR rate (%) . | 1-year PFS (%) . |
|---|---|---|---|---|---|---|
| ZUMA-5, axi-cel51 | 2 | 124 | R/R | Median previous line 3 POD24, 56% | 79 | 74 |
| ELARA, tisa-cel52 | 2 | 97 | R/R | Median previous line 4 POD24, 63% | 68 | 67 |
| TRANSCEND FL, liso-cel53 | 2 | 101 (3L+ cohort) | R/R | Median previous line 3 POD24, 54% | 94 | 81 |
| Mosunetuzumab19 | 2 | 90 | R/R | Median previous line 3 POD24, 52% | 60 | 58 |
| Epcoritamab20 | 1/2 | 128 | R/R | Median previous line 3 POD24, 42% | 63 | 18-month PFS, 49 |
| Odronextamab21 | 2 | 128 | R/R | Median previous line 3 POD24, 49% | 73 | 66 |
| InMIND, tafa-R2 vs R254 | 3 | 548 | R/R | Median previous line 1 POD24, 32% | 52 (tafa-R2) 41 (R2) | Median, 22.4 months (tafa-R2) 13.9 months (R2) |
| Mosunetuzumab-lenalidomide55 | 1b | 27 | R/R | Median previous line 1 POD24, 11% | 77 | Not reported |
| Epcoritamab-R256 | 1/2 | 111 | R/R | Median previous line 1 POD24, 38% | 87 | 21-month PFS, 80 |
| AZD048657 | 1 | 56 | R/R | Median previous line 3 POD24, 34% | 85 | 79 |
| Tazemetostat58 | 2 | 99 | R/R | Median previous line 2-3 POD24, 42%-59% (based on EZH2 mutation status) | 13 (EZH2 mutated), 4 (EZH2 wild type) | Median, 11-14 months |
| ROSEWOOD, ZO49 | 2 | 145 | R/R | Median previous line 3 POD24, 34% | 39 | Median, 28 months |
| Golcadomide with/without rituximab59 | 1/2 | 63 | R/R | Median previous line 4 (golcadomide monotherapy) Median previous line 3 (golcadomide-rituximab) | 42 (golcadomide monotherapy) 67 (golcadomide 0.4 mg + rituximab) | Median, 22 months (golcadomide monotherapy) |
| Iberdomide with obinutuzumab60 | 1/2 | 13 (FL + MZL cohort) | R/R | Median previous line 4 (all B-NHL) | 39 (FL + MZL) | Not reported |
| MORNINGSUN, mosunetuzumab22 | 1 | 30 | Front line, low tumor burden | FLIPI 3-5, 10% | 83 | Not reported |
| Mosunetuzumab-lenalidomide30 | 1b/2 | 37 | Front line, high tumor burden | Stage III-IV, 87% FLIPI 3-5, 46% | 82 | Not reported |
3L+, third-line and beyond; tafa, tafasitamab.